To evaluate the potential impact of TGF-β signaling on the tumor immune status, we correlated the tumoral pSMAD2 groups with tumor-infiltrating lymphocytes (TILs), the lymphocyte markers CD8 and FOXP3, as well as the immune checkpoint markers PD1 and PDL1 using categorized variables. Here, TGFB1 is linked to neoplasm.